This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): IP960, HMR 3270, aminocandin
Description: Aminocandin is a member of the echinocandin class of anti-fungal compounds for the treatment of a broad spectrum of systemic, invasiveinfections. This class of compound is designed to be fungicidal, that is, to kill fungi rather than fungistatic (to inhibit their growth), and tohave broad-spectrum activity against multiple fungal organisms that cause serious systemic infections. Examples of such infections includeaspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcosis and zycomycosis.
Deal Structure: Indevus Pharmaceuticals and Novexel announced in December 2006 that they signed a definitive agreement whereby Indevus will out-license theworldwide rights to aminocandin to Novexel. Indevus originally licensed worldwide rights to aminocandin from sanofi-aventis in 2003.
The terms of the agreement provide Indevus with an up front payment of $1.5 million, a payment of $2.0 million upon initiation of Phase IIclinical trials, potential milestones totaling an additional $41.0 million and royalties on all future sales of aminocandin. Additionally, Indevuswill be relieved from making significant milestone and royalty payments toits licensor. Novexel will be responsible for all future development, manufacturing and commercialization activities and costs.
In January 2009, Endo Pharmaceuticals and Indevus Pharmaceuticals announced that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for...See full deal structure in Biomedtracker
Partners: Endo International plc
Additional information available to subscribers only: